A phase 1 clinical study of CB-280 in healthy volunteers
Latest Information Update: 16 Jul 2020
At a glance
- Drugs CB 280 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
Most Recent Events
- 13 Jul 2020 This study followed by the phase 1b study in patients with cystic fibrosis (NCT04279769).
- 14 Apr 2020 Status changed from recruiting to completed, according to a Calithera Biosciences media release.
- 21 Feb 2019 According to a Calithera Biosciences media release, the study will be conducted under a United States Food and Drug Administration Investigational New Drug (IND) application and is expected to complete in 2019.